TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26846522

Group type: EXPERIMENTAL
Intervention: Motivational intervention based on spirometry results and lung age information, alongside brief health counseling (15 minutes consultation).
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Brief health counseling (5 minutes) as part of usual clinical practice.
Number of subjects: 1000
Study: 28045352

Group type: EXPERIMENTAL
Intervention: Antidepressant prescribed to older adults without MDD
Number of subjects: 231

Group type: COMPARATOR
Intervention: Antidepressant prescribed to older adults with MDD
Number of subjects: 231
Study: 22752690

Group type: EXPERIMENTAL
Intervention: cilengitide 240 mg/m(2) twice weekly
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: cilengitide 400 mg/m(2) twice weekly
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: cilengitide 600 mg/m(2) twice weekly
Number of subjects: 140

Group type: COMPARATOR
Intervention: docetaxel 75 mg/m(2) once every 3 weeks
Number of subjects: 140
Study: 22333175

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once-weekly subcutaneous injection
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 400
Study: 19587338

Group type: EXPERIMENTAL
Intervention: Raxibacumab (40 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16488485

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 101

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (Control)
Number of subjects: 101
Study: 15084930

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1+/‐0.004 mg/kg/d)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CsA or Tacrolimus
Number of subjects: 14
Study: 11263449

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 2508

Group type: EXPERIMENTAL
Intervention: Early percutaneous transluminal coronary angioplasty/coronary artery bypass grafting
Number of subjects: 2508

Group type: COMPARATOR
Intervention: Prerperfusion era (1981-1983)
Number of subjects: 2508

Group type: COMPARATOR
Intervention: Reperfusion era (1992-1996)
Number of subjects: 2508
Study: 9644480

Group type: EXPERIMENTAL
Intervention: Group One (worked with nurses experienced in the care of persons living with AIDS on a high‐acuity unit)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Group Two (precepted on an acute-care unit with no AIDS patients)
Number of subjects: 2
Study: 7785746

Group type: COMPARATOR
Intervention: Nedocromil sodium 2% eye drops, administered four times daily (n=153) for VKC
Number of subjects: 2905

Group type: COMPARATOR
Intervention: Nedocromil sodium 2% eye drops, administered four times daily (n=146) for PAC
Number of subjects: 2905

Group type: COMPARATOR
Intervention: Nedocromil sodium 2% eye drops, administered twice daily (n=677) for SAC
Number of subjects: 2905

Group type: COMPARATOR
Intervention: Nedocromil sodium 2% eye drops, administered four times daily for SAC
Number of subjects: 2905

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% eye drops (n=295) for SAC
Number of subjects: 2905

Group type: COMPARATOR
Intervention: Nedocromil sodium 2% eye drops (n=155)
Number of subjects: 2905
Study: 2204243

Group type: EXPERIMENTAL
Intervention: Bivalent Salmonella typhi-Shigella sonnei vaccine, 3 doses of 10^9 organisms each
Number of subjects: 18

Group type: COMPARATOR
Intervention: Previous infection with S. sonnei
Number of subjects: 18
Study: 313717

Group type: EXPERIMENTAL
Intervention: Isometric muscle training and percutaneous electrical stimulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard plaster cast and isometric muscle training
Number of subjects: 8
Study: 31023272

Group type: EXPERIMENTAL
Intervention: Brazilian green propolis extract at a dose of 500 mg/day for 12 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 32
Study: 27891757

Group type: EXPERIMENTAL
Intervention: Alogliptin alone (25 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin/metformin once daily (500 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin/metformin twice daily (250 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alogliptin/metformin once daily
Number of subjects: 0
Study: 25540059

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily starting 3 days preoperatively and continuing within 5 days postoperatively
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 22528588

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg/day (600 IU/day) for 8 weeks (Group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Not treated (Group B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Baseline values (Group A before treatment)
Number of subjects: 65
Study: 22147126

Group type: EXPERIMENTAL
Intervention: introducer PEG-gastropexy technique without antibiotics
Number of subjects: 18

Group type: COMPARATOR
Intervention: pull PEG with antibiotics
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: both methods
Number of subjects: 18
Study: 19008491

Group type: EXPERIMENTAL
Intervention: ALED-I intervention (Internet-delivered PA program)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (delayed intent-to-treat)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: ALED-I intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 17074945

Group type: EXPERIMENTAL
Intervention: Integrated psychological and nicotine replacement therapy intervention (8 sessions)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 298
Study: 15636169

Group type: EXPERIMENTAL
Intervention: Soy protein (SP) supplementation (40 g daily for 3 months)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Milk‐based protein (MP)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Soy protein (SP) in men
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Soy protein (SP) in women
Number of subjects: 135
Study: 11716313

Group type: EXPERIMENTAL
Intervention: Oats/milk group
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Oats/soy group
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wheat/soy group
Number of subjects: 127

Group type: COMPARATOR
Intervention: Wheat/milk group
Number of subjects: 127
Study: 9152063

Group type: EXPERIMENTAL
Intervention: Retinal S antigen alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Retinal S antigen and a mixture of soluble retinal antigens
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: A mixture of soluble retinal antigens alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7970122

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 3 months (group NL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 48 h followed by placebo for 3 months (group NS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 50
Study: 2119152

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 364631

Group type: EXPERIMENTAL
Intervention: Emepronium bromide (100 mg in 100 ml saline solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution (100 ml)
Number of subjects: 20
Study: 31818694

Group type: EXPERIMENTAL
Intervention: bioceramics wrap
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo wrap
Number of subjects: 24
Study: 31481549

Group type: EXPERIMENTAL
Intervention: PDD-guided TURBT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard white light resection
Number of subjects: 0
Study: 27860410

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25459913

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23464532

Group type: COMPARATOR
Intervention: AZD1656 10-140 mg
Number of subjects: 458

Group type: COMPARATOR
Intervention: AZD1656 20-200 mg
Number of subjects: 458

Group type: COMPARATOR
Intervention: Glipizide 5-20 mg
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Open-label AZD1656 20-200 mg
Number of subjects: 458

Group type: COMPARATOR
Intervention: AZD1656 (extension population)
Number of subjects: 458
Study: 21694588

Group type: EXPERIMENTAL
Intervention: BPTBAu (bone-patellar tendon-bone autograft)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPTBAll (BPTB allograft)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HTAu (hamstring tendon autograft)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups (BPTBAu, BPTBAll, HTAu)
Number of subjects: 0
Study: 19041436

Group type: EXPERIMENTAL
Intervention: EE 30 mcg + CMA 2 mg (Belara)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: EE 30 mcg + Desogestrel 0.15 mg (Marvelon)
Number of subjects: 45
Study: 16954556

Group type: EXPERIMENTAL
Intervention: 111In-DTPA-D-Phe1-octreotide therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transhepatic administration of 111In-DTPA-D-Phe1-octreotide
Number of subjects: 12
Study: 15142997

Group type: EXPERIMENTAL
Intervention: Hatching blastocyst stage ET (Hat ET; n = 240)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Day 3 ET (n = 240)
Number of subjects: 480
Study: 11318056

Group type: EXPERIMENTAL
Intervention: Synchronization-Continuation Task with ITI from 0.4 s to 2.2 s
Number of subjects: 0
Study: 9159033

Group type: EXPERIMENTAL
Intervention: HCV genotype 1b
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: HCV genotype 2a
Number of subjects: 217

Group type: COMPARATOR
Intervention: HCV genotypes distribution
Number of subjects: 217
Study: 7684579

Group type: EXPERIMENTAL
Intervention: HMW‐HES (high‐molecular weight hydroxyethyl starch solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LMW‐HES (low‐molecular weight hydroxyethyl starch)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3.5% gelatin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated control (15 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HMW‐HES
Number of subjects: 60
Study: 3107331

Group type: EXPERIMENTAL
Intervention: Rectal thiopentone 30 mg X kg‐1
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Methohexitone 20 mg X kg‐1
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Methohexitone 30 mg X kg‐1
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 72
Study: 30608593

Group type: EXPERIMENTAL
Intervention: Direct Contact (DC)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Hospital Episode Statistics (HES)
Number of subjects: 1812
Study: 27240681

Group type: EXPERIMENTAL
Intervention: Advice to 'be your own advocate'
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Advice to 'have someone you can rely on'
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Advice to 'think positive'
Number of subjects: 59
Study: 27748565

Group type: EXPERIMENTAL
Intervention: GOT + IOT (n=30)
Number of subjects: 51

Group type: COMPARATOR
Intervention: GOT alone (n=21)
Number of subjects: 51
Study: 24085535

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 126

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 126
Study: 23957447

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 305

Group type: COMPARATOR
Intervention: Air (atmospheric air)
Number of subjects: 305
Study: 20438223

Group type: EXPERIMENTAL
Intervention: High construal level negotiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low construal level negotiation
Number of subjects: 0
Study: 18199695

Group type: EXPERIMENTAL
Intervention: Control over food choice and access to healthy/unhealthy food options
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Preference for unhealthy food items
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Interventions to educate food providers
Number of subjects: 16
Study: 16277628

Group type: EXPERIMENTAL
Intervention: Hangover group (n = 38)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 71
Study: 12505553

Group type: EXPERIMENTAL
Intervention: Anxiety Management Training (AMT) for 9 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Progressive Relaxation (PR) for 9 weeks
Number of subjects: 20
Study: 10473234

Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 893

Group type: COMPARATOR
Intervention: Comparator (cefazolin, oxacillin, or vancomycin)
Number of subjects: 893
Study: 8661629

Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (MS group, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard thoracotomy (SP group, n = 15)
Number of subjects: 30
Study: 2050997

Group type: EXPERIMENTAL
Intervention: 55 s.c. injection course of 5 M unit recombinant human alpha‐interferon (group 1, 14 patients)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Adenine‐arabinoside (for 21 days) combined from the fourteenth day on with the same 55 s.c. injection schedule of interferon (group 2, 15 cases)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 6407408

Group type: EXPERIMENTAL
Intervention: Mitomycin C, 20 mg/m2 I.V. direct once every 6 weeks, four courses
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 31049052

Group type: EXPERIMENTAL
Intervention: Individually adjusted alpha/delta neurofeedback protocol
Number of subjects: 26
Study: 29949233

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 28480365

Group type: EXPERIMENTAL
Intervention: Acupuncture at LR3
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham acupoint
Number of subjects: 45
Study: 24585160

Group type: EXPERIMENTAL
Intervention: Mattress system with low-air-loss technology
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Backrest elevation at 45°
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Number of subjects: 20
Study: 22739368

Group type: EXPERIMENTAL
Intervention: Intervention diet (fermentable carbohydrate restriction)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Habitual diet (control)
Number of subjects: 35
Study: 19567493

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 17631795

Group type: EXPERIMENTAL
Intervention: Manipulation treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 70
Study: 15200444

Group type: EXPERIMENTAL
Intervention: High dose hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: High flux membranes
Number of subjects: 0
Study: 12759208

Group type: COMPARATOR
Intervention: Conventional vein harvest and storage in a crystalloid solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Endoscopic vein harvest and storage in crystalloid solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional harvest under continuous perfusion of the vein with 100 ml blood via the heart lung machine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Endoscopic vein harvest under continuous perfusion
Number of subjects: 80
Study: 9422580

Group type: EXPERIMENTAL
Intervention: VacFix bags for immobilization
Number of subjects: 36

Group type: COMPARATOR
Intervention: No immobilization
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: General treatment with increased radiation doses
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Use of portal images for verification
Number of subjects: 36
Study: 7866003

Group type: EXPERIMENTAL
Intervention: Valeriana officinalis var latifolia (VOL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Salvia miltiorrhiza composite injection (SMCo)
Number of subjects: 82
Study: 2502567

Group type: EXPERIMENTAL
Intervention: Topical 2% mupirocin ointment, applied three times a day for seven days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical 2% fusidic acid ointment, applied three times a day for seven days
Number of subjects: 70
Study: 800382

Group type: EXPERIMENTAL
Intervention: Ketoprofen (Orudis)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 23
Study: 31464753

Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization plus motor control exercises
Number of subjects: 32

Group type: COMPARATOR
Intervention: Motor control exercises alone
Number of subjects: 32
Study: 31392892

Group type: EXPERIMENTAL
Intervention: HIV DNA detection
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Rapid test (RT)
Number of subjects: 1301
Study: 27183325

Group type: EXPERIMENTAL
Intervention: Removal Group (RG) - granulomatous tissue was removed
Number of subjects: 60

Group type: COMPARATOR
Intervention: Left Group (LG) - granulomatous tissue was left
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (RG and LG)
Number of subjects: 60
Study: 25886378

Group type: EXPERIMENTAL
Intervention: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks with Bevacizumab (BEV) 5 mg/kg once every 2 weeks (3 doses)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks without Bevacizumab (BEV)
Number of subjects: 90
Study: 22968823

Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone injection (20 mg, 1-3 injections at 3-week intervals)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Observation-only (control group)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone injection
Number of subjects: 95
Study: 21480416

Group type: EXPERIMENTAL
Intervention: Astaxanthin 5 mg once daily for 3 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Astaxanthin 20 mg once daily for 3 weeks
Number of subjects: 23
Study: 19358618

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 838

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study: 17704979

Group type: EXPERIMENTAL
Intervention: Saffron extracts
Number of subjects: 0
Study: 15031516

Group type: EXPERIMENTAL
Intervention: Okavax (varicella vaccine)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Trimovax (MMR vaccine)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Okavax and Trimovax administered concomitantly
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Concomitant administration of Okavax and Trimovax
Number of subjects: 300

Group type: COMPARATOR
Intervention: Trimovax only
Number of subjects: 300

Group type: COMPARATOR
Intervention: Okavax only
Number of subjects: 300
Study: 11340271

Group type: EXPERIMENTAL
Intervention: Bupivacaine injected before trocar entry (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacaine injected after trocar removal (Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no bupivacaine)
Number of subjects: 45
Study: 9462438

Group type: EXPERIMENTAL
Intervention: Fluconazole 3 mg/kg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nystatin 50,000 units/kg/day in four divided doses
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 50
Study: 7935145

Group type: EXPERIMENTAL
Intervention: Barrier creams
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Hydrocarbon cream
Number of subjects: 868
Study: 3127585

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31948853

Group type: EXPERIMENTAL
Intervention: Resistance exercise and dietary protein intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 168
Study: 28689511

Group type: EXPERIMENTAL
Intervention: Group PM+ intervention (five weekly sessions of 2 hours duration delivered by local non-specialist females under supervision)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enhanced Usual Care (control group)
Number of subjects: 120
Study: 29871263

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray combined with oral montelukast
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray alone
Number of subjects: 138
Study: 26145565

Group type: EXPERIMENTAL
Intervention: High estradiol and progesterone levels
Number of subjects: 73

Group type: COMPARATOR
Intervention: Low estradiol group
Number of subjects: 73
Study: 23802989

Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy in addition to the standard rehabilitation program
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Number of subjects: 200
Study: 20978244

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (Culturelle)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (inulin alone)
Number of subjects: 36
Study: 18369657

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 14
Study: 17117294

Group type: EXPERIMENTAL
Intervention: Adequate calcium intake (1000-1500 mg/d) from dairy foods
Number of subjects: 0
Study: 12951630

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11078265

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Canadian patients
Number of subjects: 1095

Group type: COMPARATOR
Intervention: US patients
Number of subjects: 1095
Study: 8831471

Group type: EXPERIMENTAL
Intervention: 1 PT and 1 OT per 50 beds (enhanced group)
Number of subjects: 115

Group type: COMPARATOR
Intervention: 1 PT and 1 OT per 200 beds (control group)
Number of subjects: 115